1
|
Mittal S, Mallia MB. Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development. Bioorg Chem 2023; 139:106687. [PMID: 37406518 DOI: 10.1016/j.bioorg.2023.106687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 06/15/2023] [Indexed: 07/07/2023]
Abstract
Though growing evidence has been collected in support of the concept of dose escalation based on the molecular level images indicating hypoxic tumor sub-volumes that could be radio-resistant, validation of the concept is still a work in progress. Molecular imaging of tumor hypoxia using radiopharmaceuticals is expected to provide the required input to plan dose escalation through Image Guided Radiation Therapy (IGRT) to kill/control the radio-resistant hypoxic tumor cells. The success of the IGRT, therefore, is heavily dependent on the quality of images obtained using the radiopharmaceutical and the extent to which the image represents the true hypoxic status of the tumor in spite of the heterogeneous nature of tumor hypoxia. Available literature on radiopharmaceuticals for imaging hypoxia is highly skewed in favor of nitroimidazole as the pharmacophore given their ability to undergo oxygen dependent reduction in hypoxic cells. In this context, present review on nitroimidazole radiopharmaceuticals would be immensely helpful to the researchers to obtain a birds-eye view on what has been achieved so far and what can be tried differently to obtain a better hypoxia imaging agent. The review also covers various methods of radiolabeling that could be utilized for developing radiotracers for hypoxia targeting applications.
Collapse
Affiliation(s)
- Sweety Mittal
- Radiopharmaceuticals Division, Bhabha Atomic Research Center, Mumbai 400085, India.
| | - Madhava B Mallia
- Radiopharmaceuticals Division, Bhabha Atomic Research Center, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India.
| |
Collapse
|
2
|
Nguyen AT, Kim HK. Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors. Pharmaceutics 2023; 15:1840. [PMID: 37514026 PMCID: PMC10385036 DOI: 10.3390/pharmaceutics15071840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 06/21/2023] [Accepted: 06/26/2023] [Indexed: 07/30/2023] Open
Abstract
Hypoxia, a deficiency in the levels of oxygen, is a common feature of most solid tumors and induces many characteristics of cancer. Hypoxia is associated with metastases and strong resistance to radio- and chemotherapy, and can decrease the accuracy of cancer prognosis. Non-invasive imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) using hypoxia-targeting radiopharmaceuticals have been used for the detection and therapy of tumor hypoxia. Nitroimidazoles are bioreducible moieties that can be selectively reduced under hypoxic conditions covalently bind to intracellular macromolecules, and are trapped within hypoxic cells and tissues. Recently, there has been a strong motivation to develop PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazole moieties for the visualization and treatment of hypoxic tumors. In this review, we summarize the development of some novel PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazoles, as well as their physicochemical properties, in vitro cellular uptake values, in vivo biodistribution, and PET/SPECT imaging results.
Collapse
Affiliation(s)
- Anh Thu Nguyen
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
| | - Hee-Kwon Kim
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
| |
Collapse
|
3
|
Nguyen AT, Kim HK. Recent Advances of 68Ga-Labeled PET Radiotracers with Nitroimidazole in the Diagnosis of Hypoxia Tumors. Int J Mol Sci 2023; 24:10552. [PMID: 37445730 DOI: 10.3390/ijms241310552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 06/19/2023] [Accepted: 06/21/2023] [Indexed: 07/15/2023] Open
Abstract
Positron emission tomography (PET) is a noninvasive molecular imaging method extensively applied in the detection and treatment of various diseases. Hypoxia is a common phenomenon found in most solid tumors. Nitroimidazole is a group of bioreducible pharmacophores that selectively accumulate in hypoxic regions of the body. Over the past few decades, many scientists have reported the use of radiopharmaceuticals containing nitroimidazole for the detection of hypoxic tumors. Gallium-68, a positron-emitting radioisotope, has a favorable half-life time of 68 min and can be conveniently produced by 68Ge/68Ga generators. Recently, there has been significant progress in the preparation of novel 68Ga-labeled complexes bearing nitroimidazole moieties for the diagnosis of hypoxia. This review provides a comprehensive overview of the current status of developing 68Ga-labeled radiopharmaceuticals with nitroimidazole moieties, their pharmacokinetics, and in vitro and in vivo studies, as well as PET imaging studies for hypoxic tumors.
Collapse
Affiliation(s)
- Anh Thu Nguyen
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
| | - Hee-Kwon Kim
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea
| |
Collapse
|
4
|
Zhu J, Pan F, Cai H, Pan L, Li Y, Li L, Li Y, Wu X, Fan H. Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. Front Med (Lausanne) 2022; 9:945602. [PMID: 36275809 PMCID: PMC9581209 DOI: 10.3389/fmed.2022.945602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 08/31/2022] [Indexed: 11/13/2022] Open
Abstract
Lung cancer has been the leading cause of cancer-related mortality in China in recent decades. Positron emission tomography-computer tomography (PET/CT) has been established in the diagnosis of lung cancer. 18F-FDG is the most widely used PET tracer in foci diagnosis, tumor staging, treatment planning, and prognosis assessment by monitoring abnormally exuberant glucose metabolism in tumors. However, with the increasing knowledge on tumor heterogeneity and biological characteristics in lung cancer, a variety of novel radiotracers beyond 18F-FDG for PET imaging have been developed. For example, PET tracers that target cellular proliferation, amino acid metabolism and transportation, tumor hypoxia, angiogenesis, pulmonary NETs and other targets, such as tyrosine kinases and cancer-associated fibroblasts, have been reported, evaluated in animal models or under clinical investigations in recent years and play increasing roles in lung cancer diagnosis. Thus, we perform a comprehensive literature review of the radiopharmaceuticals and recent progress in PET tracers for the study of lung cancer biological characteristics beyond glucose metabolism.
Collapse
Affiliation(s)
- Jing Zhu
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China,Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China,NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China
| | - Fei Pan
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Huawei Cai
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Lili Pan
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Yalun Li
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Lin Li
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - YunChun Li
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China,Department of Nuclear Medicine, The Second People’s Hospital of Yibin, Yibin, China
| | - Xiaoai Wu
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China,Xiaoai Wu,
| | - Hong Fan
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China,*Correspondence: Hong Fan,
| |
Collapse
|
5
|
Walke GR, Meron S, Shenberger Y, Gevorkyan‐Airapetov L, Ruthstein S. Cellular Uptake of the ATSM-Cu(II) Complex under Hypoxic Conditions. ChemistryOpen 2021; 10:486-492. [PMID: 33908707 PMCID: PMC8080296 DOI: 10.1002/open.202100044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 03/08/2021] [Indexed: 12/21/2022] Open
Abstract
The Cu(II)-diacetyl-bis (N4-methylthiosemicarbazone) complex (ATSM-Cu(II)) has been suggested as a promising positron emission tomography (PET) agent for hypoxia imaging. Several in-vivo studies have shown its potential to detect hypoxic tumors. However, its uptake mechanism and its specificity to various cancer cell lines have been less studied. Herein, we tested ATSM-Cu(II) toxicity, uptake, and reduction, using four different cell types: (1) mouse breast cancer cells (DA-3), (2) human embryonic kidney cells (HEK-293), (3) breast cancer cells (MCF-7), and (4) cervical cancer cells (Hela) under normoxic and hypoxic conditions. We showed that ATSM-Cu(II) is toxic to breast cancer cells under normoxic and hypoxic conditions; however, it is not toxic to normal HEK-293 non-cancer cells. We showed that the Cu(I) content in breast cancer cell after treatment with ATSM-Cu(II) under hypoxic conditions is higher than in normal cells, despite that the uptake of ATSM-Cu(II) is a bit higher in normal cells than in breast cancer cells. This study suggests that the redox potential of ATSM-Cu(II) is higher in breast cancer cells than in normal cells; thus, its toxicity to cancer cells is increased.
Collapse
Affiliation(s)
- Gulshan R. Walke
- Department of ChemistryFaculty of Exact Sciences, and theInstitute for Nanotechnology and advanced materials (BINA)Bar-Ilan University5290002Ramat-GanIsrael
| | - Shelly Meron
- Department of ChemistryFaculty of Exact Sciences, and theInstitute for Nanotechnology and advanced materials (BINA)Bar-Ilan University5290002Ramat-GanIsrael
| | - Yulia Shenberger
- Department of ChemistryFaculty of Exact Sciences, and theInstitute for Nanotechnology and advanced materials (BINA)Bar-Ilan University5290002Ramat-GanIsrael
| | - Lada Gevorkyan‐Airapetov
- Department of ChemistryFaculty of Exact Sciences, and theInstitute for Nanotechnology and advanced materials (BINA)Bar-Ilan University5290002Ramat-GanIsrael
| | - Sharon Ruthstein
- Department of ChemistryFaculty of Exact Sciences, and theInstitute for Nanotechnology and advanced materials (BINA)Bar-Ilan University5290002Ramat-GanIsrael
| |
Collapse
|
6
|
Li H, Yao Q, Pu Z, Chung J, Ge H, Shi C, Xu N, Xu F, Sun W, Du J, Fan J, Wang J, Yoon J, Peng X. Hypoxia-activatable nano-prodrug for fluorescently tracking drug release in mice. Sci China Chem 2021. [DOI: 10.1007/s11426-020-9880-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Karamzade-Ziarati N, Manafi-Farid R, Ataeinia B, Langsteger W, Pirich C, Mottaghy FM, Beheshti M. Molecular imaging of bone metastases using tumor-targeted tracers. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF RADIOPHARMACEUTICAL CHEMISTRY AND BIOLOGY 2019; 63:136-149. [PMID: 31315347 DOI: 10.23736/s1824-4785.19.03206-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Bone metastasis is a disastrous manifestation of most malignancies, especially in breast, prostate and lung cancers. Since asymptomatic bone metastases are not uncommon, early detection, precise assessment, and localization of them are very important. Various imaging modalities have been employed in the setting of diagnosis of bone metastasis, from plain radiography and bone scintigraphy to SPECT, SPECT/CT, PET/CT, MRI. However, each modality showed its own limitation providing accurate diagnostic performance. In this regard, various tumor-targeted radiotracers have been introduced for molecular imaging of bone metastases using modern hybrid modalities. In this article we review the strength of different cancer-specific radiopharmaceuticals in the detection of bone metastases. As shown in the literature, among various tumor-targeted tracers, 68Ga DOTA-conjugated-peptides, 68Ga PSMA, 18F DOPA, 18F galacto-RGD integrin, 18F FDG, 11C/18F acetate, 11C/18F choline, 111In octreotide, 123/131I MIBG, 99mTc MIBI, and 201Tl have acceptable capabilities in detecting bone metastases depending on the cancer type. However, different study designs and gold standards among reviewed articles should be taken into consideration.
Collapse
Affiliation(s)
- Najme Karamzade-Ziarati
- Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Reyhaneh Manafi-Farid
- Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Bahar Ataeinia
- Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Werner Langsteger
- PET-CT Center Linz, Department of Nuclear Medicine, Ordensklinikum, St. Vincent's Hospital, Linz, Austria
| | - Christian Pirich
- Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University, Salzburg, Austria
| | - Felix M Mottaghy
- Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, Germany.,Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Mohsen Beheshti
- Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University, Salzburg, Austria - .,Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, Germany
| |
Collapse
|
8
|
Zhang L, Yao X, Cao J, Hong H, Zhang A, Zhao R, Zhang Y, Zha Z, Liu Y, Qiao J, Zhu L, Kung HF. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia. Mol Pharm 2019; 16:1156-1166. [PMID: 30676751 DOI: 10.1021/acs.molpharmaceut.8b01131] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Hypoxia is an important biochemical and physiological condition associated with uncontrolled growth of tumor. Measurement of hypoxia in tumor tissue may be useful in characterization of tumor progression and monitoring drug treatment. [18F]FMISO is the most widely employed radiotracer for imaging of hypoxic tissue with positron emission tomography (PET). However, it showed relatively low uptake in hypoxic tissues, which led to low target-to-background contrast in PET images. To overcome these shortcomings, two novel 2-fluoroproprioic acid esters, nitroimidazole derivatives 2-fluoropropionic acid 2-(2-nitro-imidazol-1-yl)-ethyl ester (FNPFT, [19F]5) and 2-fluoropropionic acid 2-(2-methyl-5-nitro-imidazol-1-yl)-ethyl ester (FMNPFT, [19F]8), were prepared and tested. Radiolabeling of [18F]5 and [18F]8 was accomplished in 45 min (radiochemical purity >95%, the decay-corrected radiochemical yield of [18F]5 was 11 ± 2%, and that of [18F]8 was 13 ± 2%, n = 5). In vitro cell uptake studies using EMT-6 tumor cells showed that both radiotracers [18F]5 and [18F]8 displayed significantly higher uptake in hypoxic cells than those under normoxic condition, while 2-[18F]fluoropropionic acid (2-[18F]FPA) displayed no difference. Biodistribution studies in mice bearing EMT-6 tumor showed that [18F]5, [18F]8, and 2-[18F]FPA displayed similar tumor and major organ uptakes. Tumor uptake values for all three agents were higher than those of [18F]FMISO, respectively ( P < 0.05). This is likely due to a rapid in vivo hydrolysis of [18F]5 and [18F]8 to their metabolite, 2-[18F]FPA. Micro PET imaging studies in the same EMT-6 implanted mice tumor model also demonstrated that both [18F]5 and [18F]8 displayed similar tumor uptake comparable to that of 2-[18F]FPA. In conclusion, two new fluorine-18 labeled nitroimidazole derivatives, [18F]5 and [18F]8, showed good tumor uptakes in mice bearing EMT-6 tumor. However, in vivo biodistribution results suggested that they were more likely reflect the predominance of in vivo produced metabolite, 2-[18F]FPA, which may not be related to tumor hypoxic condition.
Collapse
Affiliation(s)
- Lifang Zhang
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Xinyue Yao
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Jianhua Cao
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Haiyan Hong
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Aili Zhang
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Ruiyue Zhao
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Yan Zhang
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Zhihao Zha
- Beijing Institute for Brain Disorders , Capital Medical University , Beijing 100069 , P. R. China.,Department of Radiology , University of Pennsylvania , Philadelphia , Pennsylvania 19014 , United States
| | - Yajing Liu
- Beijing Institute for Brain Disorders , Capital Medical University , Beijing 100069 , P. R. China
| | - Jinping Qiao
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China
| | - Lin Zhu
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry , Beijing Normal University , Beijing 100875 , P. R. China.,Beijing Institute for Brain Disorders , Capital Medical University , Beijing 100069 , P. R. China
| | - Hank F Kung
- Beijing Institute for Brain Disorders , Capital Medical University , Beijing 100069 , P. R. China.,Department of Radiology , University of Pennsylvania , Philadelphia , Pennsylvania 19014 , United States
| |
Collapse
|
9
|
Abstract
Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron emission tomography (PET) and single-photon imaging, including single-photon emission computed tomography (SPECT), comprise the imaging component of nuclear medicine. These areas are distinct in that they exploit different nuclear decay processes and also different imaging technologies. In PET, images are created from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electron and is annihilated. In contrast, in single-photon imaging, images are created from the γ rays (and occasionally X-rays) directly emitted by the nucleus. Therapeutic nuclear medicine uses particulate radiation such as Auger or conversion electrons or β- or α particles. All three of these technologies are linked by the requirement that the radionuclide must be attached to a suitable vector that can deliver it to its target. It is imperative that the radionuclide remain attached to the vector before it is delivered to its target as well as after it reaches its target or else the resulting image (or therapeutic outcome) will not reflect the biological process of interest. Radiochemistry is at the core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of options with which to accomplish these goals. They also offer a wide range of options in terms of radionuclide half-lives and emission properties, providing the ability to carefully match the decay properties with the desired outcome. This Review provides an overview of some of the ways this can be accomplished as well as several historical examples of some of the limitations of earlier metalloradiopharmaceuticals and the ways that new technologies, primarily related to radionuclide production, have provided solutions to these problems.
Collapse
Affiliation(s)
- Eszter Boros
- Department of Chemistry , Stony Brook University , Stony Brook , New York 11794 , United States
| | - Alan B Packard
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.,Harvard Medical School , Boston , Massachusetts 02115 , United States
| |
Collapse
|
10
|
Zhou Y, Maiti M, Sharma A, Won M, Yu L, Miao LX, Shin J, Podder A, Bobba KN, Han J, Bhuniya S, Kim JS. Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy. J Control Release 2018; 288:14-22. [DOI: 10.1016/j.jconrel.2018.08.036] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 08/24/2018] [Accepted: 08/27/2018] [Indexed: 01/08/2023]
|
11
|
Hövener JB, Pravdivtsev AN, Kidd B, Bowers CR, Glöggler S, Kovtunov KV, Plaumann M, Katz-Brull R, Buckenmaier K, Jerschow A, Reineri F, Theis T, Shchepin RV, Wagner S, Bhattacharya P, Zacharias NM, Chekmenev EY. Parahydrogen-Based Hyperpolarization for Biomedicine. Angew Chem Int Ed Engl 2018; 57:11140-11162. [PMID: 29484795 PMCID: PMC6105405 DOI: 10.1002/anie.201711842] [Citation(s) in RCA: 228] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Revised: 02/14/2018] [Indexed: 12/22/2022]
Abstract
Magnetic resonance (MR) is one of the most versatile and useful physical effects used for human imaging, chemical analysis, and the elucidation of molecular structures. However, its full potential is rarely used, because only a small fraction of the nuclear spin ensemble is polarized, that is, aligned with the applied static magnetic field. Hyperpolarization methods seek other means to increase the polarization and thus the MR signal. A unique source of pure spin order is the entangled singlet spin state of dihydrogen, parahydrogen (pH2 ), which is inherently stable and long-lived. When brought into contact with another molecule, this "spin order on demand" allows the MR signal to be enhanced by several orders of magnitude. Considerable progress has been made in the past decade in the area of pH2 -based hyperpolarization techniques for biomedical applications. It is the goal of this Review to provide a selective overview of these developments, covering the areas of spin physics, catalysis, instrumentation, preparation of the contrast agents, and applications.
Collapse
Affiliation(s)
- Jan-Bernd Hövener
- Section Biomedical Imaging, Molecular Imaging North Competence Center (MOIN CC), Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Kiel University, Am Botanischen Garten 14, 24118, Kiel, Germany
| | - Andrey N Pravdivtsev
- Section Biomedical Imaging, Molecular Imaging North Competence Center (MOIN CC), Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Kiel University, Am Botanischen Garten 14, 24118, Kiel, Germany
| | - Bryce Kidd
- Department of Chemistry and Biochemistry, Southern Illinois University, Carbondale, IL, 62901, USA
| | - C Russell Bowers
- Department of Chemistry, University of Florida, Gainesville, FL, 32611, USA
| | - Stefan Glöggler
- Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 37077, Göttingen, Germany
- Center for Biostructural Imaging of Neurodegeneration, Von-Siebold-Strasse 3A, 37075, Göttingen, Germany
| | - Kirill V Kovtunov
- International Tomography Center SB RAS, 630090, Novosibirsk, Russia
- Department of Natural Sciences, Novosibirsk State University, Pirogova St. 2, 630090, Novosibirsk, Russia
| | - Markus Plaumann
- Department of Biometry and Medical Informatics, Otto-von-Guericke University of Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany
| | - Rachel Katz-Brull
- Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Kai Buckenmaier
- Magnetic resonance center, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
| | - Alexej Jerschow
- Department of Chemistry, New York University, 100 Washington Sq. East, New York, NY, 10003, USA
| | - Francesca Reineri
- Department of Molecular Biotechnology and Health Sciences, University of Torino, via Nizza 52, Torino, Italy
| | - Thomas Theis
- Department of Chemistry & Department of Physics, Duke University, Durham, NC, 27708, USA
| | - Roman V Shchepin
- Vanderbilt University Institute of Imaging Science (VUIIS), Department of Radiology and Radiological Sciences, 1161 21st Ave South, MCN AA-1105, Nashville, TN, 37027, USA
| | - Shawn Wagner
- Biomedical Imaging Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA
| | - Pratip Bhattacharya
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Niki M Zacharias
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Eduard Y Chekmenev
- Russian Academy of Sciences (RAS), Leninskiy Prospekt 14, Moscow, 119991, Russia
- Department of Chemistry, Karmanos Cancer Institute (KCI) and Integrative Biosciences (Ibio), Wayne State University, Detroit, MI, 48202, USA
| |
Collapse
|
12
|
Hövener J, Pravdivtsev AN, Kidd B, Bowers CR, Glöggler S, Kovtunov KV, Plaumann M, Katz‐Brull R, Buckenmaier K, Jerschow A, Reineri F, Theis T, Shchepin RV, Wagner S, Bhattacharya P, Zacharias NM, Chekmenev EY. Parawasserstoff‐basierte Hyperpolarisierung für die Biomedizin. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201711842] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jan‐Bernd Hövener
- Sektion Biomedizinische Bildgebung, Molecular Imaging North Competence Center (MOIN CC) Klinik für Radiologie und Neuroradiologie Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität Kiel Am Botanischen Garten 14 24118 Kiel Deutschland
| | - Andrey N. Pravdivtsev
- Sektion Biomedizinische Bildgebung, Molecular Imaging North Competence Center (MOIN CC) Klinik für Radiologie und Neuroradiologie Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität Kiel Am Botanischen Garten 14 24118 Kiel Deutschland
| | - Bryce Kidd
- Department of Chemistry and Biochemistry Southern Illinois University Carbondale IL 62901 USA
| | - C. Russell Bowers
- Department of Chemistry University of Florida Gainesville FL 32611 USA
| | - Stefan Glöggler
- Max Planck-Institut für Biophysikalische Chemie Am Fassberg 11 37077 Göttingen Deutschland
- Center for Biostructural Imaging of Neurodegeneration Von-Siebold-Straße 3A 37075 Göttingen Deutschland
| | - Kirill V. Kovtunov
- International Tomography Center SB RAS 630090 Novosibirsk Russland
- Department of Natural Sciences Novosibirsk State University Pirogova St. 2 630090 Novosibirsk Russland
| | - Markus Plaumann
- Institut für Biometrie und Medizinische Informatik Otto-von-Guericke-Universität Magdeburg Leipziger Straße 44 39120 Magdeburg Deutschland
| | - Rachel Katz‐Brull
- Department of Radiology Hadassah-Hebrew University Medical Center Jerusalem Israel
| | - Kai Buckenmaier
- Magnetresonanz-Zentrum Max Planck-Institut für biologische Kybernetik Tübingen Deutschland
| | - Alexej Jerschow
- Department of Chemistry New York University 100 Washington Sq. East New York NY 10003 USA
| | - Francesca Reineri
- Department of Molecular Biotechnology and Health Sciences University of Torino via Nizza 52 Torino Italien
| | - Thomas Theis
- Department of Chemistry & Department of Physics Duke University Durham NC 27708 USA
| | - Roman V. Shchepin
- Vanderbilt University Institute of Imaging Science (VUIIS) Department of Radiology and Radiological Sciences 1161 21st Ave South, MCN AA-1105 Nashville TN 37027 USA
| | - Shawn Wagner
- Biomedical Imaging Research Institute Cedars Sinai Medical Center Los Angeles CA 90048 USA
| | - Pratip Bhattacharya
- Department of Cancer Systems Imaging University of Texas MD Anderson Cancer Center Houston TX 77030 USA
| | - Niki M. Zacharias
- Department of Cancer Systems Imaging University of Texas MD Anderson Cancer Center Houston TX 77030 USA
| | - Eduard Y. Chekmenev
- Vanderbilt University Institute of Imaging Science (VUIIS) Department of Radiology and Radiological Sciences 1161 21st Ave South, MCN AA-1105 Nashville TN 37027 USA
- Russian Academy of Sciences (RAS) Leninskiy Prospekt 14 Moscow 119991 Russland
- Department of Chemistry, Karmanos Cancer Institute (KCI) and Integrative Biosciences (Ibio) Wayne State University Detroit MI 48202 USA
| |
Collapse
|
13
|
Kelada OJ, Rockwell S, Zheng MQ, Huang Y, Liu Y, Booth CJ, Decker RH, Oelfke U, Carson RE, Carlson DJ. Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [ 18F]Fluoromisonidazole ([ 18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements. Mol Imaging Biol 2018; 19:893-902. [PMID: 28409339 DOI: 10.1007/s11307-017-1083-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE The purpose of this study is to use dynamic [18F]fluoromisonidazole ([18F]FMISO) positron emission tomography (PET) to compare estimates of tumor hypoxic fractions (HFs) derived by tracer kinetic modeling, tissue-to-blood ratios (TBR), and independent oxygen (pO2) measurements. PROCEDURES BALB/c mice with EMT6 subcutaneous tumors were selected for PET imaging and invasive pO2 measurements. Data from 120-min dynamic [18F]FMISO scans were fit to two-compartment irreversible three rate constant (K 1, k 2, k 3) and Patlak models (K i). Tumor HFs were calculated and compared using K i, k 3, TBR, and pO2 values. The clinical impact of each method was evaluated on [18F]FMISO scans for three non-small cell lung cancer (NSCLC) radiotherapy patients. RESULTS HFs defined by TBR (≥1.2, ≥1.3, and ≥1.4) ranged from 2 to 85 % of absolute tumor volume. HFs defined by K i (>0.004 ml min cm-3) and k 3 (>0.008 min-1) varied from 9 to 85 %. HF quantification was highly dependent on metric (TBR, k 3, or K i) and threshold. HFs quantified on human [18F]FMISO scans varied from 38 to 67, 0 to 14, and 0.1 to 27 %, for each patient, respectively, using TBR, k 3, and K i metrics. CONCLUSIONS [18F]FMISO PET imaging metric choice and threshold impacts hypoxia quantification reliability. Our results suggest that tracer kinetic modeling has the potential to improve hypoxia quantification clinically as it may provide a stronger correlation with direct pO2 measurements.
Collapse
Affiliation(s)
- Olivia J Kelada
- Department of Therapeutic Radiology, Yale University School of Medicine, P.O. Box 208040, New Haven, CT, 06520-8040, USA.,Department of Medical Physics in Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
| | - Sara Rockwell
- Department of Therapeutic Radiology, Yale University School of Medicine, P.O. Box 208040, New Haven, CT, 06520-8040, USA.,Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA
| | - Ming-Qiang Zheng
- Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA
| | - Yiyun Huang
- Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA
| | - Yanfeng Liu
- Department of Therapeutic Radiology, Yale University School of Medicine, P.O. Box 208040, New Haven, CT, 06520-8040, USA
| | - Carmen J Booth
- Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT, USA
| | - Roy H Decker
- Department of Therapeutic Radiology, Yale University School of Medicine, P.O. Box 208040, New Haven, CT, 06520-8040, USA
| | - Uwe Oelfke
- Department of Medical Physics in Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
| | - Richard E Carson
- Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA
| | - David J Carlson
- Department of Therapeutic Radiology, Yale University School of Medicine, P.O. Box 208040, New Haven, CT, 06520-8040, USA.
| |
Collapse
|
14
|
Preparation and preliminary evaluation of a tris-metronidazole-99mTc(CO)3 complex for targeting tumor hypoxia. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-6012-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
15
|
Pell VR, Baark F, Mota F, Clark JE, Southworth R. PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts. CURRENT CARDIOVASCULAR IMAGING REPORTS 2018. [PMID: 29515752 PMCID: PMC5830463 DOI: 10.1007/s12410-018-9447-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Purpose of Review In this review, we outline the potential for hypoxia imaging as a diagnostic and prognostic tool in cardiology. We describe the lead hypoxia PET radiotracers currently in development and propose a rationale for how they should most appropriately be screened and validated. Recent Findings While the majority of hypoxia imaging agents has been developed for oncology, the requirements for hypoxia imaging in cardiology are different. Recent work suggests that the bis(thiosemicarbazone) family of compounds may be capable of detecting the subtle degrees of hypoxia associated with cardiovascular syndromes, and that they have the potential to be “tuned” to provide different tracers for different applications. Summary New tracers currently in development show significant promise for imaging evolving cardiovascular disease. Fundamental to their exploitation is their careful, considered validation and characterization so that the information they provide delivers the greatest prognostic insight achievable.
Collapse
Affiliation(s)
- Victoria R Pell
- 1School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
| | - Friedrich Baark
- 1School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
| | - Filipa Mota
- 1School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
| | - James E Clark
- 2School of Cardiovascular Medicine and Sciences, BHF Centre, King's College London, London, UK
| | - Richard Southworth
- 1School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
| |
Collapse
|
16
|
Challapalli A, Carroll L, Aboagye EO. Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging 2017; 5:225-253. [PMID: 28596947 PMCID: PMC5437135 DOI: 10.1007/s40336-017-0231-1] [Citation(s) in RCA: 102] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Accepted: 04/21/2017] [Indexed: 02/07/2023]
Abstract
PURPOSE Hypoxia is a condition of insufficient oxygen to support metabolism which occurs when the vascular supply is interrupted, or when a tumour outgrows its vascular supply. It is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance. This review provides an overview of hypoxia imaging with Positron emission tomography (PET), with an emphasis on the biological relevance, mechanism of action, highlighting advantages, and limitations of the currently available hypoxia radiotracers. METHODS A comprehensive PubMed literature search was performed, identifying articles relating to biological significance and measurement of hypoxia, MRI methods, and PET imaging of hypoxia in preclinical and clinical settings, up to December 2016. RESULTS A variety of approaches have been explored over the years for detecting and monitoring changes in tumour hypoxia, including regional measurements with oxygen electrodes placed under CT guidance, MRI methods that measure either oxygenation or lactate production consequent to hypoxia, different nuclear medicine approaches that utilise imaging agents the accumulation of which is inversely related to oxygen tension, and optical methods. The advantages and disadvantages of these approaches are reviewed, along with individual strategies for validating different imaging methods. PET is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. CONCLUSION Even though hypoxia could have significant prognostic and predictive value in the clinic, the best method for hypoxia assessment has in our opinion not been realised.
Collapse
Affiliation(s)
- Amarnath Challapalli
- Department of Clinical Oncology, Bristol Cancer Institute, Horfield Road, Bristol, United Kingdom
| | - Laurence Carroll
- Department of Surgery and Cancer, Imperial College, GN1, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W120NN United Kingdom
| | - Eric O. Aboagye
- Department of Surgery and Cancer, Imperial College, GN1, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W120NN United Kingdom
| |
Collapse
|
17
|
Vats K, Mallia MB, Mathur A, Sarma HD, Banerjee S. ‘4+1’ Mixed Ligand Strategy for the Preparation of 99m
Tc-Radiopharmaceuticals for Hypoxia Detecting Applications. ChemistrySelect 2017. [DOI: 10.1002/slct.201700150] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Kusum Vats
- Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai- 400085
- Homi Bhabha National Institute; Anushakti Nagar Mumbai- 400094 India
| | - Madhava B. Mallia
- Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai- 400085
| | - Anupam Mathur
- Radiopharmaceuticals Program; Board of Radiation and Isotope Technology; Mumbai- 400705 India
| | - Haladhar D. Sarma
- Radiation Biology and Health Science Division; Bhabha Atomic Research Centre; Mumbai- 400085
| | - Sharmila Banerjee
- Radiation Medicine Centre; Parel Mumbai- 400012 India
- Homi Bhabha National Institute; Anushakti Nagar Mumbai- 400094 India
| |
Collapse
|
18
|
Zhou Y, Bobba KN, Lv XW, Yang D, Velusamy N, Zhang JF, Bhuniya S. A biotinylated piperazine-rhodol derivative: a ‘turn-on’ probe for nitroreductase triggered hypoxia imaging. Analyst 2017; 142:345-350. [DOI: 10.1039/c6an02107g] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We developed a nitroreductase responsive theranostic probe1; it comprises biotinylated rhodol in conjunction withp-nitrobenzyl functionality.
Collapse
Affiliation(s)
- Ying Zhou
- College of Chemical Science and Technology
- Yunnan University
- 650091-Kunming
- China
| | - Kondapa Naidu Bobba
- Amrita Centre for Industrial Research & Innovation
- Amrita School of Engineering
- Coimbatore
- India
| | - Xue Wei Lv
- College of Chemical Science and Technology
- Yunnan University
- 650091-Kunming
- China
| | - Dan Yang
- College of Chemical Science and Technology
- Yunnan University
- 650091-Kunming
- China
| | - Nithya Velusamy
- Amrita Centre for Industrial Research & Innovation
- Amrita School of Engineering
- Coimbatore
- India
| | - Jun Feng Zhang
- College of Chemistry and Chemical Engineering
- Yunnan University
- Kunming
- China
| | - Sankarprasad Bhuniya
- Amrita Centre for Industrial Research & Innovation
- Amrita School of Engineering
- Coimbatore
- India
- Department of Chemical Engineering & Materials Science
| |
Collapse
|
19
|
Maulucci G, Bačić G, Bridal L, Schmidt HH, Tavitian B, Viel T, Utsumi H, Yalçın AS, De Spirito M. Imaging Reactive Oxygen Species-Induced Modifications in Living Systems. Antioxid Redox Signal 2016; 24:939-58. [PMID: 27139586 PMCID: PMC4900226 DOI: 10.1089/ars.2015.6415] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
SIGNIFICANCE Reactive Oxygen Species (ROS) may regulate signaling, ion channels, transcription factors, and biosynthetic processes. ROS-related diseases can be due to either a shortage or an excess of ROS. RECENT ADVANCES Since the biological activity of ROS depends on not only concentration but also spatiotemporal distribution, real-time imaging of ROS, possibly in vivo, has become a need for scientists, with potential for clinical translation. New imaging techniques as well as new contrast agents in clinically established modalities were developed in the previous decade. CRITICAL ISSUES An ideal imaging technique should determine ROS changes with high spatio-temporal resolution, detect physiologically relevant variations in ROS concentration, and provide specificity toward different redox couples. Furthermore, for in vivo applications, bioavailability of sensors, tissue penetration, and a high signal-to-noise ratio are additional requirements to be satisfied. FUTURE DIRECTIONS None of the presented techniques fulfill all requirements for clinical translation. The obvious way forward is to incorporate anatomical and functional imaging into a common hybrid-imaging platform. Antioxid. Redox Signal. 24, 939-958.
Collapse
Affiliation(s)
- Giuseppe Maulucci
- 1 Institute of Physics, Catholic University of Sacred Heart , Roma, Italy
| | - Goran Bačić
- 2 Faculty of Physical Chemistry, University of Belgrade , Belgrade, Serbia
| | - Lori Bridal
- 3 Laboratoire d'Imagerie Biomédicale, Sorbonne Universités and UPMC Univ Paris 06 and CNRS and INSERM , Paris, France
| | - Harald Hhw Schmidt
- 4 Department of Pharmacology and Personalised Medicine, CARIM, Faculty of Health, Medicine & Life Science, Maastricht University , Maastricht, the Netherlands
| | - Bertrand Tavitian
- 5 Laboratoire de Recherche en Imagerie, Université Paris Descartes, Hôpital Européen Georges Pompidou , Service de Radiologie, Paris, France
| | - Thomas Viel
- 5 Laboratoire de Recherche en Imagerie, Université Paris Descartes, Hôpital Européen Georges Pompidou , Service de Radiologie, Paris, France
| | - Hideo Utsumi
- 6 Innovation Center for Medical Redox Navigation, Kyushu University , Fukuoka, Japan
| | - A Süha Yalçın
- 7 Department of Biochemistry, School of Medicine, Marmara University , İstanbul, Turkey
| | - Marco De Spirito
- 1 Institute of Physics, Catholic University of Sacred Heart , Roma, Italy
| |
Collapse
|
20
|
Kit formulation for preparation and biological evaluation of a novel 99m Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia. Nucl Med Biol 2016; 43:165-70. [DOI: 10.1016/j.nucmedbio.2015.11.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 10/06/2015] [Accepted: 11/03/2015] [Indexed: 11/18/2022]
|
21
|
Zhang Q, Huang H, Chu T. In vitroandin vivoevaluation of technetium-99m-labeled propylene amine oxime complexes containing nitroimidazole and nitrotriazole groups as hypoxia markers. J Labelled Comp Radiopharm 2015; 59:14-23. [DOI: 10.1002/jlcr.3365] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Revised: 11/06/2015] [Accepted: 11/28/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Qiang Zhang
- Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science; College of Chemistry and Molecular Engineering, Peking University; Beijing 100871 China
| | - Huafan Huang
- Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science; College of Chemistry and Molecular Engineering, Peking University; Beijing 100871 China
| | - Taiwei Chu
- Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science; College of Chemistry and Molecular Engineering, Peking University; Beijing 100871 China
| |
Collapse
|
22
|
Abstract
Clinical studies using Eppendorf needle sensors have invariably documented the resistance of hypoxic human tumors to therapy. These studies first documented the need for individual patient measurement of hypoxia, as hypoxia varied from tumor to tumor. Furthermore, hypoxia in sarcomas and cervical cancer leads to distant metastasis or local or regional spread, respectively. For various reasons, the field has moved away from direct needle sensor oxygen measurements to indirect assays (hypoxia-inducible factor-related changes and bioreductive metabolism) and the latter can be imaged noninvasively. Many of hypoxia's detrimental therapeutic effects are reversible in mice but little treatment improvement in hypoxic human tumors has been seen. The question is why? What factors cause human tumors to be refractory to antihypoxia strategies? We suggest the primary cause to be the complexity of hypoxia formation and its characteristics. Three basic types of hypoxia exist, encompassing various diffusional (distance from perfused vessel), temporal (on or off cycling), and perfusional (blood flow efficiency) limitations. Surprisingly, there is no current information on their relative prevalence in human tumors and even animal models. This is important because different hypoxia subtypes are predicted to require different diagnostic and therapeutic approaches, but the implications of this remain unknown. Even more challenging, no agreement exists for the best way to measure hypoxia. Some results even suggest that hypoxia is unlikely to be targetable therapeutically. In this review, the authors revisit various critical aspects of this field that are sometimes forgotten or misrepresented in the recent literature. As most current noninvasive imaging studies involve PET-isotope-labeled 2-nitroimidazoles, we emphasize key findings made in our studies using 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide (EF5) and F-18-labeled EF5. These show the importance of differentiating hypoxia subtypes, optimizing drug pharmacology, ensuring drug and isotope stability, identifying key biochemical and physiological variables in tumors, and suggesting therapeutic strategies that are most likely to succeed.
Collapse
Affiliation(s)
- Cameron J Koch
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
| | - Sydney M Evans
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
23
|
Kim SJ, Chang S. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients. Oncol Res Treat 2015; 38:577-85. [DOI: 10.1159/000441289] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 09/25/2015] [Indexed: 11/19/2022]
|
24
|
Synthesis and evaluation of a novel 99mTcN(PNP)-complex with metronidazole isocyanide ligand as a marker for tumor hypoxia. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-4526-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
25
|
Neutral 99mTc(CO)3 complexes of “clicked” nitroimidazoles for the detection of tumor hypoxia. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-4135-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Li Z, Song X, Zhang J. Synthesis and biological evaluation of novel 99mTc labeled ornidazole xanthate complexes as potential hypoxia imaging agents. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-4125-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. Nucl Med Biol 2014; 41:600-10. [DOI: 10.1016/j.nucmedbio.2014.04.103] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 03/27/2014] [Accepted: 04/14/2014] [Indexed: 12/22/2022]
|
28
|
Mei L, Sun W, Chu T. Synthesis and biological evaluation of novel 99mTcN-labeled bisnitroimidazole complexes containing monoamine-monoamide dithiol as potential tumor hypoxia markers. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3235-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Do QN, Ratnakar JS, Kovács Z, Sherry AD. Redox- and hypoxia-responsive MRI contrast agents. ChemMedChem 2014; 9:1116-29. [PMID: 24825674 PMCID: PMC4119595 DOI: 10.1002/cmdc.201402034] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2014] [Indexed: 02/04/2023]
Abstract
The development of responsive or "smart" magnetic resonance imaging (MRI) contrast agents that can report specific biomarker or biological events has been the focus of MRI contrast agent research over the past 20 years. Among various biological hallmarks of interest, tissue redox and hypoxia are particularly important owing to their roles in disease states and metabolic consequences. Herein we review the development of redox-/hypoxia-sensitive T1 shortening and paramagnetic chemical exchange saturation transfer (PARACEST) MRI contrast agents. Traditionally, the relaxivity of redox-sensitive Gd(3+) -based complexes is modulated through changes in the ligand structure or molecular rotation, while PARACEST sensors exploit the sensitivity of the metal-bound water exchange rate to electronic effects of the ligand-pendant arms and alterations in the coordination geometry. Newer designs involve complexes of redox-active metal ions in which the oxidation states have different magnetic properties. The challenges of translating redox- and hypoxia-sensitive agents in vivo are also addressed.
Collapse
Affiliation(s)
- Quyen N. Do
- Department of Chemistry, The University of Texas at Dallas, 800 West Campbell, BE26, Richardson, TX 75080 (USA)
| | - James S. Ratnakar
- Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 (USA)
| | - Zoltán Kovács
- Department of Chemistry, The University of Texas at Dallas, 800 West Campbell, BE26, Richardson, TX 75080 (USA)
- Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 (USA)
| | - A. Dean Sherry
- Department of Chemistry, The University of Texas at Dallas, 800 West Campbell, BE26, Richardson, TX 75080 (USA)
- Advanced Imaging Research Center, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 (USA)
| |
Collapse
|
30
|
Giglio J, Dematteis S, Fernández S, Cerecetto H, Rey A. Synthesis and evaluation of a new99mTc(I)-tricarbonyl complex bearing the 5-nitroimidazol-1-yl moiety as potential hypoxia imaging agent. J Labelled Comp Radiopharm 2014; 57:403-9. [PMID: 24692093 DOI: 10.1002/jlcr.3195] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2013] [Revised: 12/09/2013] [Accepted: 02/09/2014] [Indexed: 11/08/2022]
Affiliation(s)
- J. Giglio
- Cátedra de Radioquímica, Facultad de Química; Universidad de la República; Montevideo Uruguay
| | - S. Dematteis
- Cátedra de Inmunología, Facultad de Química; Universidad de la República; Montevideo Uruguay
| | - S. Fernández
- Cátedra de Radioquímica, Facultad de Química; Universidad de la República; Montevideo Uruguay
| | - H. Cerecetto
- Área de Radiofarmacia y Radioquímica-CIN, Facultad de Ciencias; Universidad de la República; Montevideo Uruguay
| | - A. Rey
- Cátedra de Radioquímica, Facultad de Química; Universidad de la República; Montevideo Uruguay
| |
Collapse
|
31
|
Kelada OJ, Carlson DJ. Molecular imaging of tumor hypoxia with positron emission tomography. Radiat Res 2014; 181:335-49. [PMID: 24673257 DOI: 10.1667/rr13590.1] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The problem of tumor hypoxia has been recognized and studied by the oncology community for over 60 years. From radiation and chemotherapy resistance to the increased risk of metastasis, low oxygen concentrations in tumors have caused patients with many types of tumors to respond poorly to conventional cancer therapies. It is clear that patients with high levels of tumor hypoxia have a poorer overall treatment response and that the magnitude of hypoxia is an important prognostic factor. As a result, the development of methods to measure tumor hypoxia using invasive and noninvasive techniques has become desirable to the clinical oncology community. A variety of imaging modalities have been established to visualize hypoxia in vivo. Positron emission tomography (PET) imaging, in particular, has played a key role for imaging tumor hypoxia because of the development of hypoxia-specific radiolabelled agents. Consequently, this technique is increasingly used in the clinic for a wide variety of cancer types. Following a broad overview of the complexity of tumor hypoxia and measurement techniques to date, this article will focus specifically on the accuracy and reproducibility of PET imaging to quantify tumor hypoxia. Despite numerous advances in the field of PET imaging for hypoxia, we continue to search for the ideal hypoxia tracer to both qualitatively and quantitatively define the tumor hypoxic volume in a clinical setting to optimize treatments and predict response in cancer patients.
Collapse
Affiliation(s)
- Olivia J Kelada
- a Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut; and
| | | |
Collapse
|
32
|
Kadrmas DJ, Hoffman JM. Methodology for quantitative rapid multi-tracer PET tumor characterizations. Am J Cancer Res 2013; 3:757-73. [PMID: 24312149 PMCID: PMC3840410 DOI: 10.7150/thno.5201] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Accepted: 04/15/2013] [Indexed: 01/18/2023] Open
Abstract
Positron emission tomography (PET) can image a wide variety of functional and physiological parameters in vivo using different radiotracers. As more is learned about the molecular basis for disease and treatment, the potential value of molecular imaging for characterizing and monitoring disease status has increased. Characterizing multiple aspects of tumor physiology by imaging multiple PET tracers in a single patient provides additional complementary information, and there is a significant body of literature supporting the potential value of multi-tracer PET imaging in oncology. However, imaging multiple PET tracers in a single patient presents a number of challenges. A number of techniques are under development for rapidly imaging multiple PET tracers in a single scan, where signal-recovery processing algorithms are employed to recover various imaging endpoints for each tracer. Dynamic imaging is generally used with tracer injections staggered in time, and kinetic constraints are utilized to estimate each tracers' contribution to the multi-tracer imaging signal. This article summarizes past and ongoing work in multi-tracer PET tumor imaging, and then organizes and describes the main algorithmic approaches for achieving multi-tracer PET signal-recovery. While significant advances have been made, the complexity of the approach necessitates protocol design, optimization, and testing for each particular tracer combination and application. Rapid multi-tracer PET techniques have great potential for both research and clinical cancer imaging applications, and continued research in this area is warranted.
Collapse
|
33
|
Ribeiro Morais G, Falconer RA, Santos I. Carbohydrate-Based Molecules for Molecular Imaging in Nuclear Medicine. European J Org Chem 2013. [DOI: 10.1002/ejoc.201201457] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
34
|
Abstract
Imaging hypoxia using positron emission tomography (PET) is of great importance for therapy of cancer. [(18)F]Fluoromisonidazole (FMISO) was the first PET agent for hypoxia imaging, and various radiolabeled nitroimidazole derivatives such as [(18)F]fluoroerythronitroimidazole (FETNIM), [(18)F]1-α-D: -(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole (FAZA), [(18)F]2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide (EF-5), and [(18)F]fluoroetanidazole (FETA) have been developed successively. To overcome the high cost of cyclotron installation, (68)Ga-labeled nitroimidazole derivatives also have been developed. Another important hypoxia imaging agent is (64)Cu-diacetyl-bis(N (4)-methylthiosemicarbazone) ((64)Cu-ATSM), which can distribute in cancer tissue rapidly due to high lipophilicity. However, its application is limited due to high cost of radionuclide production. Although various hypoxia imaging agents have been reported and tested, hypoxia PET images still have to be improved, because of the low blood flow in hypoxic tissues and resulting low uptake of the agents.
Collapse
Affiliation(s)
- Lathika Hoigebazar
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
| | | |
Collapse
|
35
|
Mallia MB, Kumar C, Mathur A, Sarma HD, Banerjee S. On the structural modification of 2-nitroimidazole-(99m)Tc(CO)(3) complex, a hypoxia marker, for improving in vivo pharmacokinetics. Nucl Med Biol 2012; 39:1236-42. [PMID: 22938843 DOI: 10.1016/j.nucmedbio.2012.07.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2012] [Revised: 07/02/2012] [Accepted: 07/11/2012] [Indexed: 11/26/2022]
Abstract
INTRODUCTION A 2-nitroimidazole-(99m)Tc(CO)(3) complex reported earlier showed promise with respect to its uptake and retention in hypoxic tumor. However, significant uptake and slow clearance from liver imposed severe limitations towards advocating its possible practical utility. In an attempt to improving its liver clearance, an ether linkage, which is known to help in liver clearance, was introduced in the molecule. METHODS The 2-nitroimidazole iminodiacetic acid (IDA) derivative containing an ether linkage was synthesized in a five step procedure from 2-nitroimidazole. This derivative was radiolabeled using [(99m)Tc(CO)(3)(H(2)O)(3)](+) precursor complex. The corresponding Re(CO)(3) analogue was also synthesized in the macroscopic level for structural characterization. The (99m)Tc(CO)(3) complex was evaluated in an animal model bearing fibrosarcoma tumor. RESULTS The in vivo evaluation of the complex indicated that, as envisaged, introduction of the ether linkage has improved clearance from the liver. The complex also showed higher retention in tumor compared to the 2-nitroimidazole-IDA-(99m)Tc(CO)(3) complex reported earlier. Though the tumor to muscle ratio improved with time, the tumor to blood ratio did not show any significant improvement. Despite improved liver clearance, there was significant liver activity present even at 3h p.i. attributable to gradual accumulation of activity cleared from muscle and blood. CONCLUSIONS Though the introduction of ether linkage improved liver clearance of the modified 2-nitroimidazole complex, it was found that a single ether linkage was not sufficient to achieve the desirable level of clearance. Probably, a linker with multiple ether groups, such as a di- or tri-ethylene glycol spacer, may be a possible solution to this issue.
Collapse
Affiliation(s)
- Madhava B Mallia
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai-400085, India
| | | | | | | | | |
Collapse
|
36
|
Giglio J, Fernández S, Pietzsch HJ, Dematteis S, Moreno M, Pacheco JP, Cerecetto H, Rey A. Synthesis, in vitro and in vivo characterization of novel 99mTc-‘4+1’-labeled 5-nitroimidazole derivatives as potential agents for imaging hypoxia. Nucl Med Biol 2012; 39:679-86. [DOI: 10.1016/j.nucmedbio.2011.12.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Revised: 11/22/2011] [Accepted: 12/28/2011] [Indexed: 10/28/2022]
|
37
|
Shetty D, Jeong JM, Shim H. Stroma targeting nuclear imaging and radiopharmaceuticals. INTERNATIONAL JOURNAL OF MOLECULAR IMAGING 2012; 2012:817682. [PMID: 22685650 PMCID: PMC3364577 DOI: 10.1155/2012/817682] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2012] [Accepted: 02/29/2012] [Indexed: 01/27/2023]
Abstract
Malignant transformation of tumor accompanies profound changes in the normal neighboring tissue, called tumor stroma. The tumor stroma provides an environment favoring local tumor growth, invasion, and metastatic spreading. Nuclear imaging (PET/SPECT) measures biochemical and physiologic functions in the human body. In oncology, PET/SPECT is particularly useful for differentiating tumors from postsurgical changes or radiation necrosis, distinguishing benign from malignant lesions, identifying the optimal site for biopsy, staging cancers, and monitoring the response to therapy. Indeed, PET/SPECT is a powerful, proven diagnostic imaging modality that displays information unobtainable through other anatomical imaging, such as CT or MRI. When combined with coregistered CT data, [(18)F]fluorodeoxyglucose ([(18)F]FDG)-PET is particularly useful. However, [(18)F]FDG is not a target-specific PET tracer. This paper will review the tumor microenvironment targeting oncologic imaging such as angiogenesis, invasion, hypoxia, growth, and homing, and also therapeutic radiopharmaceuticals to provide a roadmap for additional applications of tumor imaging and therapy.
Collapse
Affiliation(s)
- Dinesh Shetty
- Department of Radiology and Imaging Sciences, Emory University, 1701 Uppergate Drive, C5008, Atlanta, GA 30322, USA
- Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
| | - Jae-Min Jeong
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul 110744, Republic of Korea
| | - Hyunsuk Shim
- Department of Radiology and Imaging Sciences, Emory University, 1701 Uppergate Drive, C5008, Atlanta, GA 30322, USA
- Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
| |
Collapse
|
38
|
Schweifer A, Hammerschmidt F. Preparation of nucleosides derived from 2-nitroimidazole and D-arabinose, D-ribose, and D-galactose by the Vorbrüggen method and their conversion to potential precursors for tracers to image hypoxia. J Org Chem 2011; 76:8159-67. [PMID: 21905640 PMCID: PMC3195313 DOI: 10.1021/jo200727k] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2011] [Indexed: 11/29/2022]
Abstract
2-Nitroimidazole was silylated using hexaethyldisilazane and then reacted with 1-O-acetyl derivatives of D-arabinose, D-ribose, and D-galactose in acetonitrile at mild temperatures (-20 °C to rt), catalyzed by triethylsilyl triflate (Vorbrüggen conditions). The α-anomer was formed in the former case and the β-anomers in the latter two cases (highly) selectively. When D-arabinose and D-ribose were silylated with tert-butyldiphenylsilyl chloride in pyridine at the hydroxyl groups at C-5 and acetylated at the other ones in a one-pot reaction, mixtures of anomeric 1-O-acetyl derivatives were obtained. These were coupled by the Vorbrüggen method and then deblocked at C-5 and tosylated to give precursors for tracers to image hypoxia in four steps without using Hg(CN)(2) necessary for other methods. The Vorbrüggen conditions enable a shorter route to azomycin nucleoside analogues than the previous coupling procedures.
Collapse
Affiliation(s)
- Anna Schweifer
- Institute of Organic Chemistry, University of Vienna, Währingerstrasse 38, A-1090 Vienna, Austria
| | - Friedrich Hammerschmidt
- Institute of Organic Chemistry, University of Vienna, Währingerstrasse 38, A-1090 Vienna, Austria
| |
Collapse
|
39
|
Fuks L, Gniazdowska E, Kozminski P, Mieczkowski J. Technetium(I) tricarbonyl complexed with the N-heterocyclic aldehyde thiosemicarbazones: potential precursors of the radiopharmaceuticals. J Radioanal Nucl Chem 2011. [DOI: 10.1007/s10967-011-1404-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Wang X, Jacobs MA, Fayad L. Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI. NMR IN BIOMEDICINE 2011; 24:750-63. [PMID: 21793077 PMCID: PMC3150732 DOI: 10.1002/nbm.1731] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
This article provides a literature review of the use of MRI in monitoring the treatment response of soft tissue sarcomas. The basic classification and physiology of soft tissue tumors are introduced. Then, the major treatment options for soft tissue sarcomas are summarized with brief coverage of possible responses and grading systems. Four major branches of MRI techniques are covered, including conventional T(1) - and T(2) -weighted imaging, contrast-enhanced MRI, MR diffusion and perfusion imaging, and MRS, with a focus on the tumor microenvironment. Although this literature survey focuses on recent clinical developments using these MRI techniques, research venues in preclinical studies, as well as in potential applications other than soft tissue sarcomas, are also included when comparable and/or mutually supporting. Examples from other less-discussed MRI modalities are also briefly covered, not only to complement, but also to expand, the scope and depth of information for various kinds of lesions.
Collapse
Affiliation(s)
- Xin Wang
- Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA
| | | | | |
Collapse
|
41
|
Molecular SPECT Imaging: An Overview. INTERNATIONAL JOURNAL OF MOLECULAR IMAGING 2011; 2011:796025. [PMID: 21603240 PMCID: PMC3094893 DOI: 10.1155/2011/796025] [Citation(s) in RCA: 145] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/01/2010] [Accepted: 02/05/2011] [Indexed: 12/15/2022]
Abstract
Molecular imaging has witnessed a tremendous change over the last decade. Growing interest and emphasis are placed on this specialized technology represented by developing new scanners, pharmaceutical drugs, diagnostic agents, new therapeutic regimens, and ultimately, significant improvement of patient health care. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) have their signature on paving the way to molecular diagnostics and personalized medicine. The former will be the topic of the current paper where the authors address the current position of the molecular SPECT imaging among other imaging techniques, describing strengths and weaknesses, differences between SPECT and PET, and focusing on different SPECT designs and detection systems. Radiopharmaceutical compounds of clinical as well-preclinical interest have also been reviewed. Moreover, the last section covers several application, of μSPECT imaging in many areas of disease detection and diagnosis.
Collapse
|
42
|
Zha Z, Zhu L, Liu Y, Du F, Gan H, Qiao J, Kung HF. Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging. Nucl Med Biol 2011; 38:501-8. [PMID: 21531287 DOI: 10.1016/j.nucmedbio.2010.11.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2010] [Revised: 10/29/2010] [Accepted: 11/01/2010] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Nitroimidazole (azomycin) derivatives labeled with radioisotopes have been developed as cancer imaging and radiotherapeutic agents based on the oncological hypoxic mechanism. By attaching nitroimidazole core with different functional groups, we synthesized new nitroimidazole derivatives and evaluated their potentiality as tumor imaging agents. METHODS Starting with commercially available 2-nitroimidazole, 2-fluoro-N-(2-(2-nitro-1H-imidazol-1-yl)ethyl)acetamide (NEFA, [(19)F]7) and 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 2-fluoroacetate (NEFT, [(19)F]8), as well as radiolabeling precursors, the bromo-substituted analogs were quickly synthesized through a three-step synthetic pathway. The precursors were radiolabeled with [(18)F]F(-)/18-crown-6/KHCO(3) in dimethyl sulfoxide at 90°C for 10 min followed by purification with an Oasis HLB cartridge. Biodistribution studies were carried out in EMT-6 tumor-bearing mice. The uptake (%ID/g) in tumors and normal tissues were measured at 30 min postinjection. Liquid chromatography-electrospray ionization mass spectrometry (LC/MS) was used to distinguish metabolites from parent drugs in urine and plasma of rat injected with "cold" NEFA ([(19)F]7) and NEFT ([(19)F]8). RESULTS Two radiotracers, [(18)F]NEFA ([(18)F]7) and [(18)F]NEFT ([(18)F]8), were prepared with average yields of 6%-7% and 9%-10% (not decay corrected). Radiochemical purity for both tracers was >95% as determined by HPLC. Biodistribution studies in EMT-6 tumor-bearing mice indicated that the tumor to blood and tumor to liver ratios of both [(18)F]7 (0.96, 0.61) and [(18)F]8 (0.98, 1.10) at 30 min were higher than those observed for [(18)F]FMISO (1) (0.91, 0.59), a well-investigated azomycin-type hypoxia radiotracer. Liquid chromatography-electrospray ionization mass spectrometry analysis demonstrated that fluoroacetate was the main in vivo metabolite for both NEFA ([(19)F]7) and NEFT ([(19)F]8). CONCLUSIONS In this research, two new fluorine-18 labeled 2-nitroimidazole derivatives, [(18)F]7 and [(18)F]8, both of which containing in vivo hydrolyzable group, were successfully prepared. Further biological evaluations are warranted to investigate their potential as PET radioligands for imaging tumor.
Collapse
Affiliation(s)
- Zhihao Zha
- Key Laboratory of Radiopharmaceuticals, Beijing Normal University, Ministry of Education, Beijing 100875, P.R. China
| | | | | | | | | | | | | |
Collapse
|
43
|
Giglio J, Fernández S, Rey A, Cerecetto H. Synthesis and biological characterisation of novel dithiocarbamate containing 5-nitroimidazole 99mTc-complexes as potential agents for targeting hypoxia. Bioorg Med Chem Lett 2011; 21:394-7. [DOI: 10.1016/j.bmcl.2010.10.130] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Revised: 10/24/2010] [Accepted: 10/26/2010] [Indexed: 11/29/2022]
|
44
|
Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, Hahn SM, Driesbaugh J, Smith D, Prendergast S, Evans SM. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010; 37:2048-59. [PMID: 20585774 DOI: 10.1007/s00259-010-1517-y] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2010] [Accepted: 06/01/2010] [Indexed: 12/29/2022]
Abstract
PURPOSE The primary purpose of this study was to assess the biodistribution and radiation dose resulting from administration of (18)F-EF5, a lipophilic 2-nitroimidazole hypoxia marker in ten cancer patients. For three of these patients (with glioblastoma) unlabeled EF5 was additionally administered to allow the comparative assessment of (18)F-EF5 tumor uptake with EF5 binding, the latter measured in tumor biopsies by fluorescent anti-EF5 monoclonal antibodies. METHODS (18)F-EF5 was synthesized by electrophilic addition of (18)F(2) gas, made by deuteron bombardment of a neon/fluorine mixture in a high-pressure gas target, to an allyl precursor in trifluoroacetic acid at 0° then purified and administered by intravenous bolus. Three whole-body images were collected for each of ten patients using an Allegro (Philips) scanner. Gamma counts were determined in blood, drawn during each image, and urine, pooled as a single sample. PET images were analyzed to determine radiotracer uptake in several tissues and the resulting radiation dose calculated using OLINDA software and standard phantom. For three patients, 21 mg/kg unlabeled EF5 was administered after the PET scans, and tissue samples obtained the next day at surgery to determine EF5 binding using immunohistochemistry techniques (IHC). RESULTS EF5 distributes evenly throughout soft tissue within minutes of injection. Its concentration in blood over the typical time frame of the study (∼3.5 h) was nearly constant, consistent with a previously determined EF5 plasma half-life of ∼13 h. Elimination was primarily via urine and bile. Radiation exposure from labeled EF5 is similar to other (18)F-labeled imaging agents (e.g., FDG and FMISO). In a de novo glioblastoma multiforme patient, focal uptake of (18)F-EF5 was confirmed by IHC. CONCLUSION These results confirm predictions of biodistribution and safety based on EF5's characteristics (high biological stability, high lipophilicity). EF5 is a novel hypoxia marker with unique pharmacological characteristics allowing both noninvasive and invasive measurements.
Collapse
Affiliation(s)
- Cameron J Koch
- Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Fully automated radiosynthesis of [18F]Fluoromisonidazole with single neutral alumina column purification: optimization of reaction parameters. J Radioanal Nucl Chem 2010. [DOI: 10.1007/s10967-010-0644-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Ueda M, Kudo T, Kuge Y, Mukai T, Tanaka S, Konishi H, Miyano A, Ono M, Kizaka-Kondoh S, Hiraoka M, Saji H. Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1alpha. Eur J Nucl Med Mol Imaging 2010; 37:1566-74. [PMID: 20428865 DOI: 10.1007/s00259-010-1467-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2009] [Accepted: 03/29/2010] [Indexed: 12/01/2022]
Abstract
PURPOSE Hypoxia-inducible factor-1 (HIF-1) plays an important role in malignant tumour progression. For the imaging of HIF-1-active tumours, we previously developed a protein, POS, which is effectively delivered to and selectively stabilized in HIF-1-active cells, and a radioiodinated biotin derivative, (3-(123)I-iodobenzoyl)norbiotinamide ((123)I-IBB), which can bind to the streptavidin moiety of POS. In this study, we aimed to investigate the feasibility of the pretargeting method using POS and (123)I-IBB for rapid imaging of HIF-1-active tumours. METHODS Tumour-implanted mice were pretargeted with POS. After 24 h, (125)I-IBB was administered and subsequently, the biodistribution of radioactivity was investigated at several time points. In vivo planar imaging, comparison between (125)I-IBB accumulation and HIF-1 transcriptional activity, and autoradiography were performed at 6 h after the administration of (125)I-IBB. The same sections that were used in autoradiographic analysis were subjected to HIF-1alpha immunohistochemistry. RESULTS (125)I-IBB accumulation was observed in tumours of mice pretargeted with POS (1.6%ID/g at 6 h). This result is comparable to the data derived from (125)I-IBB-conjugated POS-treated mice (1.4%ID/g at 24 h). In vivo planar imaging provided clear tumour images. The tumoral accumulation of (125)I-IBB significantly correlated with HIF-1-dependent luciferase bioluminescence (R=0.84, p<0.01). The intratumoral distribution of (125)I-IBB was heterogeneous and was significantly correlated with HIF-1alpha-positive regions (R=0.58, p<0.0001). CONCLUSION POS pretargeting with (123)I-IBB is a useful technique in the rapid imaging and detection of HIF-1-active regions in tumours.
Collapse
Affiliation(s)
- Masashi Ueda
- Radioisotopes Research Laboratory, Kyoto University Hospital, Faculty of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Mallia MB, Subramanian S, Mathur A, Sarma HD, Venkatesh M, Banerjee S. Synthesis and evaluation of 2-, 4-, 5-substituted nitroimidazole-iminodiacetic acid-99mTc(CO)3 complexes to target hypoxic tumors. J Labelled Comp Radiopharm 2010. [DOI: 10.1002/jlcr.1754] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
48
|
Dearling JLJ, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol 2010; 37:237-43. [PMID: 20346863 DOI: 10.1016/j.nucmedbio.2009.11.004] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2009] [Revised: 11/19/2009] [Accepted: 11/23/2009] [Indexed: 12/12/2022]
Abstract
Cu(II)-ATSM continues to be investigated, both in the laboratory and in the clinic, as a tumor hypoxia imaging agent. However, meaningful interpretation of these images requires a more complete understanding of the mechanism by which the tracer is trapped within the cell. Cu(II)-ATSM is a simple molecule and its biochemical interaction with cells is similarly simple, mainly based upon redox chemistry. Here we suggest that the trapping mechanism is biphasic. The first phase is a reduction/oxidation cycle involving thiols and molecular oxygen. This can be followed by interaction with proteins in the mitochondria leading to more permanent retention of the tracer. The uptake mechanism is complicated by this second step because of the changes in the cell resulting from hypoxia, such as an increase in nicotinamide adenine dinucleotide (NADH) redox state and differences in cellular biochemistry and cell proteomes. These changes may lead to differences in the extent of trapping and retention of the (64)Cu in different cell types. For example, copper uptake might be increased in cells with lower pH due to the lower stability of metal bis(thiosemicarbazones) under acidic conditions. Reaction rates with cellular reductants also vary with pH, which differs between cellular organelles. For Cu(II)-ATSM to reach its full potential, more complete characterization of the mechanism of cellular trapping in different cell types is required.
Collapse
Affiliation(s)
- Jason L J Dearling
- Division of Nuclear Medicine, Department of Radiology, Children's Hospital Boston and Harvard Medical School, Boston, MA 02115, USA.
| | | |
Collapse
|
49
|
Koch CJ, Shuman AL, Jenkins WT, Kachur AV, Karp JS, Freifelder R, Dolbier WR, Evans SM. The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol 2010; 85:1137-47. [PMID: 19995239 DOI: 10.3109/09553000903242172] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE Tumour hypoxia affects cancer biology and therapy-resistance in both animals and humans. The purpose of this study was to determine whether EF5 ([2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide]) binding and/or radioactive drug uptake correlated with single-dose radiation response in 9L gliosarcoma tumours. MATERIALS AND METHODS Twenty-two 9L tumours were grown in male Fischer rats. Rats were administered low specific activity (18)F-EF5 and their tumours irradiated and assessed for cell survival and hypoxia. Hypoxia assays included EF5 binding measured by antibodies against bound-drug adducts and gamma counts of (18)F-EF5 tumour uptake compared with uptake by normal muscle and blood. These assays were compared with cellular radiation response (in vivo to in vitro assay). In six cases, uptake of tumour versus muscle was also assayed using images from a PET (positron emission tomography) camera (PENN G-PET). RESULTS The intertumoural variation in radiation response of 9L tumour-cells was significantly correlated with uptake of (18)F-labelled EF5 (i.e., including both bound and non-bound drug) using either tumour to muscle or tumour to blood gamma count ratios. In the tumours where imaging was performed, there was a significant correlation between the image analysis and gamma count analysis. Intertumoural variation in cellular radiation response of the same 22 tumours was also correlated with mean flow cytometry signal due to EF5 binding. CONCLUSION To our knowledge, this is the first animal model/drug combination demonstrating a correlation of radioresponse for tumour-cells from individual tumours with drug metabolism using either immunohistochemical or non-invasive techniques.
Collapse
Affiliation(s)
- Cameron J Koch
- Departments of Radiation Oncology, University of Pennsylvania, 195 John Morgan Bldg., 37th St & Hamilton Walk, Philadelphia, PA, 19104-6072, USA.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Abrantes AM, Serra MES, Gonçalves AC, Rio J, Oliveiros B, Laranjo M, Rocha-Gonsalves AM, Sarmento-Ribeiro AB, Botelho MF. Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells. Nucl Med Biol 2009; 37:125-32. [PMID: 20152711 DOI: 10.1016/j.nucmedbio.2009.11.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2009] [Revised: 11/03/2009] [Accepted: 11/07/2009] [Indexed: 11/30/2022]
Abstract
Colorectal cancer is one of the most common malignancies in the Western world and is an example of a solid tumour in which hypoxia is a common feature and develops because of the inability of the vascular system to supply adequate amounts of oxygen to growing tumours. Hypoxia effects on tumour cell biology can be detected and characterized using different methods. The use of imaging with gamma-emitting radionuclides to detect hypoxic tissue was first suggested by Chapman in 1979 [N Engl J Med 301 (1979) 1429-1432]. (99m)Tc-4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime, also known as (99m)Tc-HL-91, has been among the most studied hypoxia markers. The objective of this study was to correlate the uptake of (99m)Tc-HL-91 and (99m)Tc-MIBI in colon cancer cells under normoxic and hypoxic conditions and to compare this information with some parameters such as oxidative stress and mitochondrial dysfunction of the cells analyzed by flow cytometry. Our results show that the in vitro (99m)Tc-HL-91 uptake is higher in hypoxic conditions, which is confirmed by the decreased uptake of (99m)Tc-MIBI. Flow cytometry results demonstrate that hypoxic conditions used are not enough to induce cellular death, but are responsible for the alterations in the intracellular redox environment, namely, increase of ROS production, proteic pimonidazol-derived adduct formation and alteration in the mitochondrial membrane permeability. Therefore, these results confirm that (99m)Tc-HL-91 is a radiopharmaceutical with favourable characteristics for detecting hypoxia.
Collapse
Affiliation(s)
- Ana Margarida Abrantes
- Biophysics/Biomathematics Institute, IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
| | | | | | | | | | | | | | | | | |
Collapse
|